1 |
Choi GS. Hair characteristics and androgenetic alopecia in Koreans. J Korean Med Assoc 2013;56(1):45-54.
DOI
|
2 |
Press release: Androgenetic alopecia patients steadily increased by 4.8% year! Health Insurance Review & Assessment. URL=http://www.hira.or.kr/dummy.do?pgmid=HIRAA020041000000&cmsurl=/cms/notice/02/1325758_24959.html&subject='남성 탈모증' 환자 年 4.8%씩 꾸준히 증가!#none, (Accessed on Aug 20, 2015).
|
3 |
KIMS book in book pharmacy guide. KIMS 2014; Issue 4, 29. Seoul: KIMS Co., Ltd.
|
4 |
Cash TF. Attitudes, behaviors, and expectations of men seeking medical treatment for male pattern hair loss: results of a multinational survey. Curr Med Res Opin 2009;25(7):1811-20.
DOI
|
5 |
Lee WS. Updates of Alopecia. Drug information. 2012;38(4). URL=http://old.yakup.com/pharminfo/pharminfo2012-04-01.php, (Accessed on Aug 20, 2015).
|
6 |
National health Information Portal, http://health.mw.go.kr. URL=http://health.mw.go.kr/HealthInfoArea/HealthInfo/View.do?idx=370. (Accessed on Aug 20, 2015).
|
7 |
Donovan J, Goldstein BG, Goldstein AO. Treatment of androgenetic alopecia in men. Last updated: Jul. 21, 2014. Uptodate, URL=www.uptodate.com, (Accessed on Aug 20, 2015).
|
8 |
Hoffmann R. Steroidogenic isoenzymes in human hair and their potential role in adnrogenetic alopecia. Dermatology 2003;206(2):85-95.
DOI
|
9 |
Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010;63(2):252-8.
DOI
|
10 |
A service of the U.S. National Institutes of Health. A Long-term Study to determine safety and efficacy of dutasteride in male subjects with Androgenetic alopecia. URL=http://clinicaltrials.gov/ct2/show/NCT01831791, (Accessed on Aug 20, 2015).
|
11 |
Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5-alpha reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride vs. finasteride. J Am Acad Dermatol 2006;55:1014-23.
DOI
|
12 |
Rogers NE, Avram MR. medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008;59(4):547-66.
DOI
|
13 |
Gubelin HW, Barboza MJ, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014;70(3):489-98.
DOI
|
14 |
Druginfo. www.druginfo.co.kr. URL=http://www.druginfo.co.kr/detail/product.aspx?pid=14544, (Accessed on Aug 20, 2015).
|
15 |
Lee JS. 'Age' emerged as the new variable on competition of treatment for alopecia, MSD-GSK. www.docdocdoc.co.kr. URL=http://www.docdocdoc.co.kr/news/newsview.php?newscd=2014111100014, (Accessed on Aug 20, 2015).
|
16 |
Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63(4):709-15.
DOI
|
17 |
Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89(5):2179-84.
DOI
|
18 |
Druginfo. www.druginfo.co.kr. URL=http://www.druginfo.co.kr/detail/product.aspx?pid=39860, (Accessed on Aug 21, 2015).
|
19 |
Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79(3):703-6.
DOI
|
20 |
Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol 2014;53(11):1351-7.
DOI
|
21 |
Tsai JC, Flynn GL, Weiner N, et al. Effect of minoxidil concentration on the deposition of drug and vehicle into the skin. Int J Pharm 1993;96:111-7.
DOI
|
22 |
Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007;57(5):767-74.
DOI
|
23 |
Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex med 2011;8(6):1747-53.
DOI
|
24 |
Yim E, Nole KL, Tosti A. -Reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes 2014;21(6):493-8.
DOI
|
25 |
US Food and Drug Administration. Drug safety and Availability; Questions and Answers: Finasteride label changes. URL=http://google2.fda.gov/search?q=Drug+safety+and+Availability%3B+Questions+and+Answers%3A+Finasteride+label+changes&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=archive%3AYes&output=xml_no_dtd&getfields=*, (Accessed on Aug 21, 2015).
|